Content Rheum
Interleukin-23 Inhibition
FAQs
Click a title to watch the FAQ
​
Define, Compare, and Contrast Humoral and Cell-Mediated Immunity.
​
​
What is the Role Of the IL23/IL17 Axis In Rheumatic Disease?
​
Provide Immunologic Rationale for IL23 Directed Therapy in PsA, PsO, and IBD.
​
Why is Binding CD64+ Important When Discussing IL23 Directed Therapy?
​
How Does Axial PsA Differ from AS Clinically, Genetically, and Radiographically?
​
How Do You Interpret Radiographic Progression Using Modified-vdHS or mTSS?
​
How Does Real-World Evidence Differ From Randomized Controlled Trials?
​
How Do You Interpret cDAPSA/DAPSA and MDA?
​
How Do IL-23 and IL-17 Inhibitors Differ in Clinical Efficacy?
​
What is the Effect of Guselkumab on Structural Damage in PsA?
​
What Is the Clinical Significance of Structural Damage in PsA?
​
How Does The Design of APEX Differ From DISCOVER-2 To Enrich For Structural Damage?
​
Why Is the mvdH-S Score Used Most Often in PsA Trials?
​
What Is the Normal Role of CD64 in Innate and Adaptive Immunity?
​
What Is the Correlation of CD64 and IL-23 Expression in Inflamed Joint, Skin, and Gut Tissue?
​
What Validated Screening Tools Help Identify Potential PsA/SpA or IBD to Prompt Referral to Rheumatology or Gastroenterology?
​
What Is the Efficacy of Switching MOA to Guselkumab After Inadequate Response to a Single TNFi?
​
What Role Does Power Doppler Ultrasound Play in Detecting Subclinical Inflammation/Enthesitis?
​
What is the Importance of MRI in Assessing Axial Disease Manifestations in PsA?​​
MEDICATION REVIEWS
Click a title to watch the review
​
Describe the Mechanism of Action of Guselkumab.
​​​
What Is Non-Responder Imputation and How is it Utilized in Clinical Trials?
​
How Is Guselkumab Dosed in PsO, PsA, and IBD?
​
What Is the Safety Profile of Guselkumab in PsO and PsA?
​
What Is the Efficacy of Guselkumab Across the GRAPPA Domains?
​
What Is the Real-World Evidence of Guselkumab in PsA?​
​
What Is the Evidence For Guselkumab Efficacy In Inhibiting The Progression of Structural Damage?
​
What are the Laboratory Monitoring Recommendations for Guselkumab Across PSO, PsA, and IBD?
​
​
What Is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis (jPsA)?
JOURNAL CLUBS
Click a title to read the journal
​
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23.
​
​
​
Long-term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis).
​
Guselkumab Binds To CD64+ IL-23–Producing Myeloid Cells to Neutralize IL-23 Signals
​
DISCOVER-2 Severe PsA Publication
​
​
PODCASTS
Click a title to play the podcast
​
The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD.
​
CD64+ Binding: Description, Relevance, and Potential Clinical Implications.
​
The Clinical Utility of Guselkumab in Axial PsA.
​
The Relative Persistency and Effectiveness of Guselkumab in the Real-W orld.
​
Unpacking the Differences: IL-23 Inhibitors in Focus
​
​Protecting Joints: Inhibiting Structural Damage in PsA With Guselkumab
​
SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
